Valence 로고
인기
로그인
Loading data for SXTP — first visit, this takes a few seconds.

관심목록에 추가

60 Degrees Pharmaceutical...

NasdaqCM: SXTP · 실시간 가격 · USD
1.13
+0.00 (0.00%)
종가 기준: Aug 21, 2026, 8:00 PM
1.13
+0.00%
애프터마켓: 4:10 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

60 Degrees Pharmaceuticals Inc.(SXTP) 주가, 분석 및 데이터

0.00%

데이터 없음

매수호가0.81
시가총액3.97M
매출 (ttm)1.21M
순이익 (ttm)-8.62M
n/a
-2.71
n/a
-0.32
P/B (ttm)-0.43
P/S (ttm)3.27
실적 발표일Aug 12, 2025
매도호가1.42
거래량17,481
평균 거래량 (20일)109,008
시가1.15
전일 종가1.13
일중 범위1.10 - 1.15
52주 범위1.02 - 8.62
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

SXTP 소개

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trial...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Jul 12, 2023
직원 수 3
상장 거래소 NasdaqCM
티커 SXTP
웹사이트 https://www.60degreespharma.com
전체 기업 정보

재무 실적

2025년 60 Degrees Pharmaceuticals의 매출은 1.01M로, 전년 607.57K 대비 65.49% 증가했습니다. 순이익은 -7.37M로, -7.32% 감소했습니다.

재무제표

어닝 서프라이즈

60 Degrees Pharmaceuticals가 Aug 14, 2026에 분기 실적을 발표했습니다:
  • 매출 $162.09K 예상치 하회 $0, 및 -0.89% 전년 대비 감소.
  • EPS -0.86 예상치 상회 0.03, 및 80.14% 전년 대비 성장.

다음 실적 발표

60 Degrees Pharmaceuticals Inc.의 실적 발표 예정일은 Aug 12, 2025, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드
news image

1주 전 · Zacks

Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates

Harrow (HROW) delivered earnings and revenue surprises of -47.83% and -0.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

news image

3개월 전 · Zacks

Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +50.00% and +33.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stoc...

news image

3개월 전 · Zacks

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -33.33% and -3.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

news image

4개월 전 · Zacks

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

news image

5개월 전 · Insider Monkey

60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODA

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) is one of the best up and coming penny stocks to buy. On February 2, 60 Degrees Pharmaceuticals announced a partnership with GoodRx to enhance the afforda...

2 페이지 중 1